Press Releases

EIN Presswire

Hybrid-use facility advances health care, public safety and emergency management education while strengthening Missouri's workforce and emergency preparedness.

GlobeNewswire, Inc.

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-term BLA completion for HR BCG-unresponsive NMIBC expected fourth quarter 2026 Phase 3 BOND-003 Cohort C...

GlobeNewswire, Inc.

PARIS and NEW YORK , Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pasqal Holding SAS ("Pasqal"), a global leader in neutral-atom quantum computing, today announced that its joint registration statement on Form F-4 (the "Registration Statement") with...

GlobeNewswire, Inc.

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral...

GlobeNewswire, Inc.

-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 -- -- Favorable arbitration resolution with...

GlobeNewswire, Inc.

VANCOUVER, British Columbia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- General Fusion Group Ltd. (“General Fusion” or the “Company”) (NASDAQ: GFUZ), a leader in the global race to commercialize fusion energy, today announced it will host a conference call...

GlobeNewswire, Inc.

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today...

GlobeNewswire, Inc.

CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing in Q3 2026 Budoprutug clinical programs continue to advance, with data...

GlobeNewswire, Inc.

Immunocore reports second quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in Phase 3 TEBE-AM trial for previously treated...

GlobeNewswire, Inc.

Over 60 clinical sites activated in registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes; Enrollment remains on track for completion in Q4 2026, with topline data expected in 2H 2027 Breakthrough T1D awarded a grant to...

GlobeNewswire, Inc.

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027 Phase 2 TRITON trial of Descartes-08 in myositis on track with data from...

GlobeNewswire, Inc.

BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal...

GlobeNewswire, Inc.

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be presented in a poster at the European...

GlobeNewswire, Inc.

Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related macular degeneration (AMD); on track to...

EIN Presswire

Six new podcasts and the expansion of ALIVE STUDIOS underscores the companys commitment to amplifying Black voices and producing conversations that transform.

GlobeNewswire, Inc.

Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine Anticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027 Enrollment...

GlobeNewswire, Inc.

Plans to initiate a registrational Phase 3 program evaluating abdakibart in hidradenitis suppurativa (HS) in the first half of 2027 Expanded pipeline with AVTX-010, a long-acting next-generation anti-IL-1β antibody, with IND submission planned for...

GlobeNewswire, Inc.

Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026 Company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with...

Macao Government News

MACAU, August 5 - The Faculty of Medicine (FMD) (formerly the Faculty of Health Sciences) at the University of Macau (UM) organised two sessions of the Health Sciences Summer Camp, attracting more than 70 senior secondary school students from 35...

EIN Presswire

KYIV, UKRAINE, August 6, 2026 /⁨EINPresswire.com⁩/ -- Uzbekistan has significantly raised its economic expectations.